CKR-5 Antibody (R22/7): sc-32304
- CKR-5 Antibody (R22/7) is a mouse monoclonal IgG1 κ, cited in 4 publications, provided at 200 µg/ml
- raised against a synthetic peptide near the N-terminus of CKR-5 of human origin
- recommended for detection of CKR-5 of human origin by WB, IP, IF, IHC(P) and FCM
- available conjugated to either phycoerythrin or FITC for IF, IHC(P) and FCM
- m-IgG Fc BP-HRP, m-IgG1 BP-HRP and m-IgGκ BP-HRP are the preferred secondary detection reagents for CKR-5 Antibody (R22/7) for WB and IHC(P) applications. These reagents are now offered in bundles with CKR-5 Antibody (R22/7) (see ordering information below).
QUICK LINKS
SEE ALSO...
CKR-5 Antibody (R22/7) is a mouse monoclonal IgG1 antibody that detects CKR-5 in human samples through various applications including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry, and flow cytometry (FCM). CKR-5, a member of the C-C chemokine receptor family, plays a crucial role in the immune response by acting as a receptor for chemokines that guide the migration of immune cells to sites of inflammation. This receptor is particularly significant as a coreceptor for HIV, facilitating viral entry into host cells. The interaction between CKR-5 and HIV envelope protein is essential for viral infection of macrophages, which are key players in the immune system. Understanding CKR-5 structure and function is vital for developing therapeutic strategies against HIV and other diseases where immune cell trafficking is disrupted. Anti-CKR-5 antibody (R22/7) provides a valuable tool for researchers studying immune response dynamics and viral infection mechanisms, enabling deeper insights into potential interventions.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
CKR-5 Antibody (R22/7) References:
- C-C chemokine receptor type five (CCR5): An emerging target for the control of HIV infection. | Barmania, F. and Pepper, MS. 2013. Appl Transl Genom. 2: 3-16. PMID: 27942440
- Knockdown of C-C Chemokine Receptor 5 (CCR5) is Protective Against Cerebral Ischemia and Reperfusion Injury. | Victoria, ECG., et al. 2017. Curr Neurovasc Res. 14: 125-131. PMID: 28294064
- C-C Chemokine Receptor Type 5 (CCR5)-Mediated Docking of Transferred Tregs Protects Against Early Blood-Brain Barrier Disruption After Stroke. | Li, P., et al. 2017. J Am Heart Assoc. 6: PMID: 28768648
- The CCL5/CCR5 Axis in Cancer Progression. | Aldinucci, D., et al. 2020. Cancers (Basel). 12: PMID: 32630699
- CCR5 Activation Promotes NLRP1-Dependent Neuronal Pyroptosis via CCR5/PKA/CREB Pathway After Intracerebral Hemorrhage. | Yan, J., et al. 2021. Stroke. 52: 4021-4032. PMID: 34719258
- TGFβ1+CCR5+ neutrophil subset increases in bone marrow and causes age-related osteoporosis in male mice. | Li, J., et al. 2023. Nat Commun. 14: 159. PMID: 36631487
- Microglial-to-neuronal CCR5 signaling regulates autophagy in neurodegeneration. | Festa, BP., et al. 2023. Neuron. 111: 2021-2037.e12. PMID: 37105172
- The Role and Therapeutic Targeting of CCR5 in Breast Cancer. | Hamid, R., et al. 2023. Cells. 12: PMID: 37759462
- CCR5 and CCL5 in metastatic colorectal cancer. | Schlechter, BL. and Stebbing, J. 2024. J Immunother Cancer. 12: PMID: 38719543
- Role of C-C chemokine receptor type 5 in pathogenesis of malaria and its severe forms. | Ziliotto, M., et al. 2024. Int J Immunogenet. 51: 369-379. PMID: 39449652
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CKR-5 Antibody (R22/7) | sc-32304 | 200 µg/ml | $322.00 | |||
CKR-5 Antibody (R22/7): m-IgG Fc BP-HRP Bundle | sc-536737 | 200 µg Ab; 10 µg BP | $361.00 | |||
CKR-5 Antibody (R22/7): m-IgGκ BP-HRP Bundle | sc-533898 | 200 µg Ab; 40 µg BP | $361.00 | |||
CKR-5 Antibody (R22/7): m-IgG1 BP-HRP Bundle | sc-544788 | 200 µg Ab; 20 µg BP | $361.00 | |||
CKR-5 Antibody (R22/7) FITC | sc-32304 FITC | 200 µg/ml | $336.00 | |||
CKR-5 Antibody (R22/7) PE | sc-32304 PE | 200 µg/ml | $349.00 |